Oragenics, Inc.
OGENAMEXHealthcare● Active
$0.61
+$0.02(+2.61%)
Market Cap$2750038
P/E Ratio—
52W High$5.24
52W Low$0.5
Oragenics, Inc. (OGEN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
OGEN · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 8, 2026EPS Actual
-$0.51
Est. -$90.00 · +99.4%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 8, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
OGEN reports quarterly as a AMEX-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$72.00 | — | — | — | — | — |
| ◌ Q2 FY2026 | May 18, 2026 | — | — | — | — | — | — |
| ▲ Q2 FY2026 | May 8, 2026 | -$90.00 | -$0.51 | +99.4% | — | — | — |
| ▲ Q1 FY2026 | Feb 26, 2026 | -$90.00 | -$0.54 | +99.4% | — | — | — |
| — Q4 FY2025 | Nov 7, 2025 | — | -$1.96 | — | — | — | — |
| — Q3 FY2025 | Aug 8, 2025 | — | -$3.10 | — | — | — | — |
| — Q2 FY2025 | May 9, 2025 | — | -$3.60 | — | — | — | — |
| — Q1 FY2025 | Mar 14, 2025 | — | -$0.11 | — | — | — | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$72.00
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 18, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 8, 2026Beat
EPS Actual
-$0.51
EPS Est.
-$90.00
EPS Surpr.
+99.4%
Revenue
—
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
-$0.54
EPS Est.
-$90.00
EPS Surpr.
+99.4%
Revenue
—
Q4 FY2025
Nov 7, 2025
EPS Actual
-$1.96
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 8, 2025
EPS Actual
-$3.10
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 9, 2025
EPS Actual
-$3.60
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 14, 2025
EPS Actual
-$0.11
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2029 | $-90.00 | $-90.00 | $-90.00 | 1 |
| Q2 FY2029 | $-90.00 | $-90.00 | $-90.00 | 1 |
| Q1 FY2029 | $-90.00 | $-90.00 | $-90.00 | 1 |
| Q4 FY2028 | $-90.00 | $-90.00 | $-90.00 | 1 |
| Q3 FY2028 | $-90.00 | $-90.00 | $-90.00 | 1 |
| Q2 FY2028 | $-90.00 | $-90.00 | $-90.00 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 8, 2026 | +99.4% | $0.61 | $0.60 | -2.61% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +99.4% | $0.79 | $0.88 | +11.09% |
| — Q4 FY2025 | Nov 7, 2025 | — | $1.12 | $1.12 | +0.00% |
| — Q3 FY2025 | Aug 8, 2025 | — | $1.30 | $1.16 | -10.77% |
| — Q2 FY2025 | May 9, 2025 | — | $5.40 | $5.06 | -6.30% |
| — Q1 FY2025 | Mar 14, 2025 | — | $8.62 | $8.40 | -2.55% |
| — Q4 FY2024 | Nov 13, 2024 | — | $10.92 | $10.20 | -6.59% |
| — Q3 FY2024 | Aug 9, 2024 | — | $32.40 | $42.00 | +29.63% |
Q2 FY2026-2.61%
Report Date
May 8, 2026
EPS Beat/Miss
+99.4%
Price Before
$0.61
Price After
$0.60
Q1 FY2026+11.09%
Report Date
Feb 26, 2026
EPS Beat/Miss
+99.4%
Price Before
$0.79
Price After
$0.88
Q4 FY2025+0.00%
Report Date
Nov 7, 2025
EPS Beat/Miss
—
Price Before
$1.12
Price After
$1.12
Q3 FY2025-10.77%
Report Date
Aug 8, 2025
EPS Beat/Miss
—
Price Before
$1.30
Price After
$1.16
Q2 FY2025-6.30%
Report Date
May 9, 2025
EPS Beat/Miss
—
Price Before
$5.40
Price After
$5.06
Q1 FY2025-2.55%
Report Date
Mar 14, 2025
EPS Beat/Miss
—
Price Before
$8.62
Price After
$8.40
Q4 FY2024-6.59%
Report Date
Nov 13, 2024
EPS Beat/Miss
—
Price Before
$10.92
Price After
$10.20
Q3 FY2024+29.63%
Report Date
Aug 9, 2024
EPS Beat/Miss
—
Price Before
$32.40
Price After
$42.00
Avg Beat Reaction+4.24%
Beat Rate2 / 8 quarters
Largest Move+29.63% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: OGEN ends December
Oragenics, Inc. (OGEN) most recently reported earnings on May 8, 2026 for Q2 FY2026, posting EPS of $-0.51 — beating the analyst consensus of $-90.00 by +99.4%. OGEN has beaten EPS estimates for 2 consecutive quarters. The next OGEN earnings date is expected around September 1, 2026.
Each quarter, investors track OGEN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. OGEN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
OGEN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
OGEN earnings · 5 questionsOragenics, Inc.'s next earnings report is expected around September 1, 2026. OGEN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; OGEN historically reports after market close (AMC).
OGEN earnings datewhen is OGEN earningsOGEN next earnings datewhen does OGEN report earningsOGEN earnings calendar
▸ Source: FMP · Oragenics, Inc. SEC filings · US GAAP · Oragenics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026